Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA.

Thumbnail
View/Open
Date
2017-08
ICR Author
Author
Bozkurt, MF
Virgolini, I
Balogova, S
Beheshti, M
Rubello, D
Type
Journal Article
Metadata
Show full item record
Abstract
Purpose & methods Neuroendocrine neoplasms are a heterogenous group of tumours, for which nuclear medicine plays an important role in the diagnostic work-up as well as in the targeted therapeutic options. This guideline is aimed to assist nuclear medicine physicians in recommending, performing, reporting and interpreting the results of somatostatin receptor (SSTR) PET/CT imaging using 68 Ga-DOTA-conjugated peptides, as well as 18 F-DOPA imaging for various neuroendocrine neoplasms.Results & conclusion The previous procedural guideline by EANM regarding the use PET/CT tumour imaging with 68 Ga-conjugated peptides has been revised and updated with the relevant and recent literature in the field with contribution of distinguished experts.
URI
https://repository.icr.ac.uk/handle/internal/1089
DOI
Collections
Subject
Humans
Neuroendocrine Tumors
Gallium Radioisotopes
Dihydroxyphenylalanine
Heterocyclic Compounds, 1-Ring
Peptides
Receptors, Somatostatin
Image Interpretation, Computer-Assisted
Tissue Distribution
Quality Control
Practice Guidelines as Topic
Positron Emission Tomography Computed Tomography
Research team
Translational Molecular Imaging
Language
eng
Date accepted
2017-05-09
License start date
2017-08
Citation
European journal of nuclear medicine and molecular imaging, 2017, 44 (9), pp. 1588 - 1601